key: cord-0740804-uj85m07z
authors: Ho Wong, Andrew Kam; Woodhouse, Isaac; Schneider, Frank; Kulpa, Deanna A.; Silvestri, Guido; Maier, Cheryl L.
title: Broad Auto-Reactive IgM Responses are Common in Critically Ill Patients Including Those with COVID-19
date: 2021-05-28
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2021.100321
sha: 93689c27ac7c84d67b8e62ff6066c0c3249ca999
doc_id: 740804
cord_uid: uj85m07z

The pathogenesis of severe COVID-19 remains poorly understood. While several studies suggest that immune dysregulation plays a central role, the key mediators of this process are yet to be defined. Here, we demonstrate that plasma from a high proportion (93%) of critically ill COVID-19 patients, but not healthy controls, contains broadly auto-reactive immunoglobulin M (IgM), and less frequently auto-reactive IgG or IgA. Importantly, these auto-IgM preferentially recognize primary human lung cells in vitro, including pulmonary endothelial and epithelial cells. By using a combination of flow cytometry, analytical proteome microarray technology, and LDH-release cytotoxicity assays, we identify high-affinity, complement-fixing, auto-reactive IgM directed against 260 candidate auto-antigens, including numerous molecules preferentially expressed on the cellular membranes of pulmonary, vascular, gastrointestinal, and renal tissues. These findings suggest that broad IgM-mediated autoimmune reactivity may be involved in the pathogenesis of severe COVID-19, thereby identifying a potential target for therapeutic interventions.

Although SARS-CoV-2, the etiological agent for COVID-19, is initially and 31 preferentially tropic for respiratory cellular targets 1-3 , its pathogenetic effects can be 32 widespread. Indeed, systemic inflammation and dysregulated hemostasis are 33 hallmark characteristics of severe COVID-19 4,5 . The mechanisms responsible for 34 clinical progression to severe COVID-19, which involves acute respiratory distress 35 syndrome (ARDS) 6,7 remain poorly understood and appear to be multifactorial in 36 nature. In this context, a relatively underexplored mechanistic pathway relates to 37 autoimmunity. Historically, autoantibodies generated during the immune response to 38 other infectious diseases have been observed 8 . More recently, autoantibodies that 39 neutralize type-1 interferons were described in severe adult COVID-19 9 , as have 40 autoantibodies against self-antigens associated with systemic lupus erythematosus 41 and Sjogren's disease in severe pediatric COVID-19 10 . Additional reports of 42 antiphospholipid autoantibodies have been associated with thrombotic events 11,12 , 43 thereby linking immune dysregulation with thrombosis in severe COVID-19 13 . These 44 observations underscore the need to closely examine the intersection of 45 autoantibody-associated immunopathology and severe COVID-19, particularly in 46 pulmonary and vascular sites. 47 percentage of cells that stained positively for IgM antibodies was far greater than 72

IgA or IgG, suggesting higher circulating auto-reactive IgM titers. Although COVID 73 ICU patients were associated with higher circulating interleukin-6 (IL-6) and C-74 reactive protein (CRP) (Supplemental Figure 1a- Figure 1e ). In addition, and despite median levels not reaching 94 statistical significance, COVID ICU patients tended to have higher absolute levels of 95 target cell binding to HULEC-5a and HPAEC cells as compared to all other cohorts, 96

including non-COVID ICU, suggesting higher auto-IgM antibody titers (Supplemental 97 Figure 1e ). Interestingly, we did not find any correlation between hospitalization day 98 and auto-IgM level in COVID ICU patient plasma (Supplemental Figure 1h) . Given 99 this, as well as the higher frequency of detection and autoantibody levels, we chose 100 to focus additional studies specifically on auto-reactive IgM. Overall, this first set of 101 data revealed that high-titer auto-reactive IgM are frequently detected in critically ill 102 patients, including those with severe COVID-19, and that the reactivity in COVID ICU 103 patients is most pronounced against cells of pulmonary origin. Herein we identify the presence of auto-reactive IgM as a common feature in 208 critically ill patients, including those with COVID-19. These auto-IgM have broad 209 reactivity, and while they are significantly increased in critically ill versus non-critically 210 ill COVID patients, they are not necessarily a unique feature of COVID, as non-211 COVID ICU patients also demonstrated a high prevalence of auto-IgM in our study. 212

Nevertheless, auto-IgM directed against certain human pulmonary epithelial cells 213 was significantly increased in COVID ICU patients compared to non-COVID ICU 214 patients, and was capable of fixing complement and inducing target cell death in 215 vitro.

The identification of auto-reactive IgM as a potential contributing factor to the 218 pathogenesis of severe COVID-19 has two immediate implications. First, this 219 observation may explain how COVID-19 is disproportionately more serious in the 220 elderly 26 , who typically manifest higher plasma levels of circulating auto-reactive 221 antibodies 27 . This phenomenon would be exacerbated by decreases in functional T 222 follicular helper cells that promote antibody class switching 28 , a process associated 223 with better disease outcomes 29 . Given that IgM levels peak within a week of the 224 clinical onset of COVID-19 and persist at similar levels for weeks thereafter 30,31 , the 225 elderly face a protracted period where there may be steadfast secretion of auto-226 reactive IgM that maintain relatively low affinity for the same epitope without either 227 switching to alternate antibody class types or undergoing somatic hypermutation 228 and affinity maturation. In this perspective, the elderly may be more prone to severe 229 COVID-19 due to a more protracted exposure to the cytopathic effects of auto-230 reactive IgM. 231 232 Secondly, it is conceivable that this type of immunopathology can be limited by 233 therapeutic interventions that inhibit the IgM-complement axis. In the immediate 234 term, this approach could mitigate the SARS-CoV-2 associated alveolar damage and 235 ARDS 32-34 , and consequently protect against mortality 35 

Gender, male 5 (55%)

Gender, male 5 (42%)

Supplemental Table 1: Patient demographics and characteristics related to plasma samples shown in Figures 1 and 2

was determined by a two-tailed Spearman test. LDH release assays were performed 623 once per patient per cell type, given highly limited availability of test sample. 624